L-Dopa is the mainstay of Parkinson's disease therapy; this drug is usually administered
orally, but it is extensively metabolized in the gastrointestinal tract, so that relatively little …

Background: Parkinson's disease is an aggressive and progressive neurodegenerative
disorder that depletes dopamine (DA) in the central nervous system. Dopamine replacement …

ABSTRACT Introduction: Parkinson's Disease (PD) is a neurodegenerative disorder of the
central nervous system (CNS) characterized by motor dysfunctions, such as bradykinesia …

A range of amide derivatives of l-dopa were synthesized and investigated for their
pharmacological activity and their ability to be converted to l-dopa using the unilaterally 6 …

Introduction: Current Parkinson's disease (PD) therapy is essentially symptomatic, and l-
Dopa (LD), is the treatment of choice in more advanced stages of the disease. However …

l-Dopa, the metabolic precursor of dopamine, is the treatment of choice for the symptomatic
relief of the advanced stages of Parkinson's disease. The oral bioavailability of l-dopa …

Parkinson's disease (PD) is a progressive, neurodegenerative disorder which involves the
loss of dopaminergic neurons of the substantia nigra pars compacta. Current therapy is …

The treatment of Parkinson's disease (PD) has not been consistently modified for more than
60 years. L-DOPA, the blood–brain barrier permeable precursor prodrug of dopamine, is to …

l-DOPA, the immediate biological precursor of dopamine, is still considered the drug of
choice in the treatment of Parkinson's disease. However, therapy with l-DOPA is associated …

Intraperitoneal administration of the 2‐tetrahydropyranylmethyl, phenoxyethyl, ethyl, 2‐
hydroxypropyl and methyl ester prodrugs of L‐dopa produced locomotor activity in reserpine …